Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates

WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2017.